Essential Premium

Biopharma Hedge Funds Diverge in March as Avoro Surges

Returns were mixed amid market volatility, though Janus Henderson is bullish on the sector for the rest of the year.

Investor Advocates Ask FASB to Reconsider Guidance on Secondaries

Secondary funds’ returns are “artificially inflated” by the practice, say critics.

Sponsored

Optimizing the Efficient Frontier: Opportunistic Credit Amid a Capital Structure Reset

Greenlight’s Recovery Trade Pays Off

A long‑overlooked position in Acadia Healthcare surged in the first quarter, vaulting the stock into Greenlight Capital’s top five holdings.

Related Content

Hedge Fund VC Activity Reveals Biopharma’s Fading Momentum

Stephen Taub

After a Record Year, TCI Hits a Speed Bump

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram